Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 19/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.70 |
| ▸ | RELA | Q04206 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973115 | 0.91 | SLC40A1 (0.83) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL16286079 | 0.87 | SLC40A1 (0.78) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL11973674 | 0.85 | SLC40A1 (1.00) | SLC40A1NFKBIARELA | |
| SCHEMBL11973246 | 0.85 | SLC40A1 (1.00) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL11973446 | 0.84 | SLC40A1 (1.00) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL11973648 | 0.84 | SLC40A1 (0.75) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL11973854 | 0.84 | SLC40A1 (0.79) | SLC40A1NFKBIARELA | |
| SCHEMBL28104848 | 0.83 | SLC40A1 (0.71) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL11973679 | 0.83 | SLC40A1 (1.00) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL11972920 | 0.83 | SLC40A1 (1.00) | SLC40A1NFKBIARELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885NFKBIA 277/4885RELA 1102/4885 |
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | NFKBIA, BACE1, BACE2 | SLC40A1 3410/4885NFKBIA 1/4885RELA 10/4885 |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | NFKBIA, BACE1, BACE2 | SLC40A1 3410/4885NFKBIA 1/4885RELA 10/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885NFKBIA 277/4885RELA 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.